TFF PHARMACEUTICALS INC (TFFP)
US87241J2033 - Common Stock
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Friday?
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Top movers analysis in the middle of the day on 2024-11-15: top gainers and losers in today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Let's have a look at the gap up and gap down stocks in today's session.
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
TFF Pharmaceuticals Announces It Will Wind Down Operations
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its...
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
Newly published data in the Journal of Drug Delivery Science and Technology demonstrate more uniform drug distribution in the lung compared with other...
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution...
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to...
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the second quarter ...
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and...
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company...
3 52-Week-Low Losers Ready to Become Big-Time Stock Winners
52-week-low losers may be your ticket to finding excellent stocks to buy. Take a look at these three buy-rated (potential) winners.
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to...
TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
TFFP stock results show that TFF Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the first quarter o...
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation...
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only...
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the fourth quarter ...
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical...
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from...
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation
Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC...
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...
TFF Pharmaceuticals Announces Update on Clinical Programs
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant...
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Company management will also be participating in one-on-one meetings.
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023
TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2023.
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the first quarter o...
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023
TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2023.
TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the second quarter ...